Introduction：Basic information about CAS 63610-09-3|Lodoxamide tromethamine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Lodoxamide tromethamine |
|---|
| CAS Number | 63610-09-3 | Molecular Weight | 553.90500 |
|---|
| Density | / | Boiling Point | 827.5ºC at 760 mmHg |
|---|
| Molecular Formula | C19H28ClN5O12 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 454.3ºC |
|---|
Names
| Name | Lodoxamidetromethamine |
|---|
| Synonym | More Synonyms |
|---|
Lodoxamide tromethamine BiologicalActivity
| Description | Lodoxamide tromethamine (U 42585 E) is a medication for the treatment of prophylaxis of mast cell-mediated allergic disease. |
|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Histamine ReceptorSignaling Pathways >>Immunology/Inflammation >>Histamine ReceptorResearch Areas >>Inflammation/Immunology |
|---|
| In Vitro | lodoxamide inhibits compound 48/80-induced histamine release and ionophore-induced 45Ca influx with associated histamine release in purified rat peritoneal mast cells[1]. |
|---|
| In Vivo | Lodoxamide has been demonstrated to have cromolyn-like activity when studied in the rat peritoneal mast cell assay (PCA) model3 and in Ascaris antigen-sensitized rhesus monkeys. When given intravenously, orally, or intrabronchially by aerosol, lodoxamide significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge in Ascaris-sensitized. anesthetized rhesus monkeys[1]. Addition of lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution results in a marked decrease in lung reperfusion injury as demonstrated by increased oxygenation, decreased microvascular permeability, and increased compliance[2]. Patients treated with lodoxamide tromethamine demonstrate an improvement in daytime breathing difficulty, cough, sputum production, and sleep[3]. |
|---|
| References | [1]. Watt GD, et al. Protective effect opf lodoxamide tromethamine on allergen inhalation challenge. J Allergy Clin Immunol. 1980 Oct;66(4):286-94. [2]. Barr ML, et al. Addition of a mast cell stabilizing compound to organ preservation solutions decreases lung reperfusion injury. J Thorac Cardiovasc Surg. 1998 Mar;115(3):631-6; discussion 636-7. [3]. Mann JS, et al. Inhaled lodoxamide tromethamine in the treatment of perennial asthma: a double-blind placebo-controlled study. J Allergy Clin Immunol. 1985 Jul;76(1):83-90. |
|---|
Chemical & Physical Properties
| Boiling Point | 827.5ºC at 760 mmHg |
|---|
| Molecular Formula | C19H28ClN5O12 |
|---|
| Molecular Weight | 553.90500 |
|---|
| Flash Point | 454.3ºC |
|---|
| Exact Mass | 553.14200 |
|---|
| PSA | 330.01000 |
|---|
| InChIKey | JJOFNSLZHKIJEV-UHFFFAOYSA-N |
|---|
| SMILES | N#Cc1cc(NC(=O)C(=O)O)c(Cl)c(NC(=O)C(=O)O)c1.NC(CO)(CO)CO.NC(CO)(CO)CO |
|---|
| Storage condition | -20℃ |
|---|
Safety Information
Synonyms
| LodoxaMide troMethaMineon |
| Lodoxamide (tromethamine) |
